Context: Chronic starvation is characterized by GH resistance, and obesity is characterized by decreased GH secretion. In both extremes, IGF1 levels may be low and androgen levels may be abnormal. Objective: To investigate the determinants of IGF1 and GH across the weight spectrum in women. Design: Cross-sectional study. Setting: Clinical research center. Study participants: In total, 32 women had participated in the study: 11 women with anorexia nervosa (AN), 11 normal-weight women, and 10 obese women of comparable mean age. Intervention: None. Main outcome measures: Pooled hourly overnight serum samples assayed for IGF1, GH, estradiol (E 2 ), testosterone, SHBG, insulin, free fatty acids, and trunk fat. Results: Free testosterone was higher in obese women and lower in women with AN than in normalweight women, and was the only independent (and positive) predictor of IGF1 levels, accounting for 14% of the variability (PZ0.032) in the group as a whole. This relationship was stronger when obese women were excluded, with free testosterone accounting for 36% of the variability (PZ0.003). Trunk fat accounted for 49% of the variability (P!0.0001) of GH, with an additional 7% of the variability attributable to E 2 (PZ0.042) in the group as a whole, but was not a significant determinant of GH secretion when obese women were excluded. Conclusions: Free testosterone is a significant determinant of IGF1 levels in women across the body weight spectrum. In contrast, GH secretion is differentially regulated at the extremes of the weight spectrum.
Introduction
It has been recognized since the early 1960s, concomitant with the development of GH assays with sufficient specificity and sensitivity to detect changes in concentrations, that starvation results in increased GH secretion (1) and that obesity is associated with a decrease in serum GH levels (2) . Visceral adiposity (3, 4) , increased insulin secretion (5) , and elevated free fatty acids (6) (7) (8) have been demonstrated to be strong determinants of GH secretion in obesity. In chronically undernourished patients, low insulin-like growth factor 1 (IGF1) levels appear to stimulate GH production via a feedback mechanism (9) .
The determinants of IGF1 levels across the weight spectrum are less well understood. Although GH secretion is known to be an important determinant of IGF1 production, chronic starvation is associated with GH resistance and relatively low IGF1 levels, and obesity is associated with decreased GH secretion and a decrease in IGF1 production, but not to the degree that might be expected based on the degree of reduced GH secretion. As GH stimulates lipolysis independent of IGF1 effects, which are largely anabolic, increased GH secretion in starvation serves the function of mobilizing fat stores in the setting of reduced energy availability. However, the mechanisms underlying the development of GH resistance in states of chronic undernutrition or the increased GH sensitivity in obesity are not as well established. Recently and importantly, GH-induced activation of the JAK/STAT signaling pathway has been shown to be reduced in muscle and fat from human subjects during fasting (10) . However, the factors contributing to GH resistance under these conditions are not well understood. The low levels of IGF1 in anorexia nervosa (AN) and relatively preserved levels in obesity cannot be attributed to abnormalities in binding globulin levels, cleavage or action, as IGF1 bioactivity is reduced in AN (11) and preserved in obesity (12) . In contrast, insulin plays an important role by modulating GH binding in the liver, as has been shown by Leung et al. (13) in a hepatoma cell culture model. In this experimental model, increasing concentrations of insulin increased hepatic GH receptor protein and GH binding. Gonadal steroids may also be determinants of GH and hepatic IGF1 production. Estrogens stimulate GH release in some, but not all, experimental models, and may therefore drive IGF1 levels through this mechanism (14) . However, oral estrogen decreases hepatic production of IGF1 (15) by suppressing GH-induced JAK2 phosphorylation (16) .
Testosterone exerts direct independent stimulatory effects on GH and IGF1 release in men (17) . Likewise, we have recently shown that testosterone levels independently predict IGF1 levels in obese women with normal reproductive function, who have androgen levels at the higher end of the normal range (4), but whether androgens are important determinants in women with low androgen levels is unknown. Our findings in obese eumenorrheic women are consistent with data demonstrating that women with polycystic ovary syndrome have higher IGF1 levels than women without the syndrome of comparable weight (18) . In addition, healthy women of reproductive age receiving oral contraceptives containing progestins with greater androgenecity and postmenopausal women receiving hormone replacement therapy with greater androgenecity have higher IGF1 levels than those receiving preparations of lower androgenecity (19) . Although we have shown in a large group of women with AN that androgen levels are reduced (20) , it is not known whether this is a significant determinant of GH resistance in women with AN.
Our aim was to investigate the determinants of GH and IGF1 levels in women across the weight spectrum, from severe undernutrition to marked obesity. We hypothesized that in very low-weight women, as in obesity, trunk fat mass would be a significant determinant of endogenous GH concentrations, and androgen levels would be important determinants of IGF1 levels. We therefore studied women with AN, obesity, and normal-weight controls with overnight sampling for GH, IGF1, testosterone, SHBG, estradiol (E 2 ), insulin, and free fatty acids.
Subjects and methods

Subjects
We studied 32 female ambulatory, community-dwelling subjects who were recruited through advertising. Inclusion criteria for all groups included ages 18-45 years, and for normal-weight and obese women, eumenorrhea. Women with AN fulfilled all DSM-IV diagnostic criteria for AN, including weight !85% of ideal body weight and amenorrhea for at least 3 months. Exclusion criteria for all groups included hypothalamic or pituitary disorders, hypothyroidism, hyperthyroidism, estrogen or glucocorticoid use, and diabetes mellitus.
Materials and methods
The study was approved by the Partners Healthcare Inc. Institutional Review Board, and written informed consent was obtained from each study participant. Each obese and normal-weight participant was admitted during the follicular phase of the menstrual cycle to the Clinical Research Center at the Massachusetts General Hospital. As all women with AN were amenorrheic, their study visits were not timed with respect to menstrual periods or other events. Serum was collected every hour for 12 h starting at 2000 h under standardized conditions. Subjects were served dinner between 1800 and 1900 h, and were not offered breakfast until after the 0800 h blood draw. Vigorous activity, including exercise, was prohibited during this admission. Equal aliquots of serum from each hour sample were combined into one 12-h pooled sample. Clinical characteristics, but none of the endocrine data reported here, on a subset of the subjects studied were reported in previous publications (4, 12, 21, 22) .
Biochemical analyses
Serum samples were collected and stored at K80 8C. Serum total IGFI levels were measured using a solid-phase, enzyme-labeled chemiluminescent immunometric assay on the Immulite 2000 automated immunoanalyzer (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) with an inter-assay coefficient of variation (CV) of w4%. Serum total GH levels were measured using an IRMA (Diagnostic Systems Laboratories, Webster, TX, USA) with a sensitivity of 0.01 ng/ml and with an inter-assay CV of 3-5%. E 2 , insulin, and SHBG were measured by automated immunoassay (Architect; Abbott Diagnostics). The lower limit of detection of E 2 was 10 pg/ml, with an intra-assay CV of 1-6%. The lower limit of detection of insulin was 1.0 mU/ml, with an intra-assay CV of 2-5% and with an inter-assay CV of 2-10%. The lower limit of detection of SHBG was 0.01 nmol/l, with an intra-assay CV of 6-10%. Serum testosterone levels were measured by a solid-phase RIA Coat-A-Count RIA kit (Siemens Medical Solutions Diagnostics) with a minimum detection limit of 2.2 pg/ml and an intra-assay CV of 1-2%. Free testosterone levels were calculated from total testosterone and SHBG using the laws of mass action (23) . Nonesterified fatty acids were measured on an automated immunoanalyzer (Architect; Abbott Diagnostics) using a commercially available kit (Wako Chemicals USA, Richmond, VA, USA) with a sensitivity of 0.0014 mEq/l and with an intra-assay CV of !1%.
Body composition measures
Body composition was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic QDR 4500 scanner (Hologic Inc., Waltham, MA, USA), with an accuracy error for body fat mass of 1.7% and for fat-free mass of 2.4% (24) .
Statistical analysis
JMP Statistical Discoveries software (version 4.0.2, SAS Institute, Inc., Cary, NC, USA) was used for statistical analyses. Variables were log-transformed to approximate a normal distribution, and means were compared with an overall ANOVA. Corrections for multiple comparisons were performed using the Tukey-Kramer method. Univariate regression models were constructed after log transformation of variables, and Pearson's coefficients are reported, except for correlations with IGF1, for which quadratic fits were used. As a secondary analysis, dummy variables for AN and obesity were entered into least squares regression models examining the relationships between GH and both body mass index (BMI) and trunk fat, and between IGF1 and androgen levels. Stepwise regression models were constructed to investigate independent predictors of mean GH and IGFI levels. The following log-transformed variables were entered into the stepwise regression models: trunk fat mass, insulin, free fatty acid, E 2 and free testosterone levels. Statistical significance was defined as P value !0.05. Results are expressed as meanGS.E.M.
Results
Clinical characteristics of study subjects and endocrine data
Clinical characteristics and endocrine data are presented in Table 1 . We studied 11 women with AN (BMI%18.0 kg/m 2 ), 11 normal-weight (19.0!BMI !25 kg/m 2 ), and 10 obese (BMIR30 kg/m 2 ) women of comparable age. Mean BMI differed between the groups, as designed, with women with AN and obesity having lower and higher BMIs, respectively, than the controls.
Endocrine data
Mean pooled overnight GH levels were strongly inversely associated with BMI (RZK0.74, P!0.0001; Fig. 1A ) and trunk fat (RZK0.70, P!0.0001) for the group as a whole (Fig. 1B) . When dummy variables for the obese group and the group with AN were entered into the models, BMI (PZ0.009) and trunk fat (PZ0.003) remained significant predictors of GH, but the dummy variables were not, except for obesity, which was a predictor of GH after controling for trunk fat (PZ0.009).
Mean pooled overnight GH levels were lower in the obese than the normal-weight women and the group with AN (obese: 0.76G0.1 ng/ml, normal-weight: 3.4G0.5 ng/ml, AN: 3.8G0.6 ng/ml, P!0.0001). Pooled IGF1 levels were quadratically related to both BMI (R 2 Z0.22, PZ0.03; Fig. 1C ) and trunk fat (R 2 Z0.30, P!0.006; Fig. 1D ), with lower mean levels in the women with AN and those with obesity compared with the normal-weight group (obese: 164G16 ng/ml, normal-weight: 222G25 ng/ml, AN: 147G11 ng/ml, PZ0.016). Mean GH levels were positively associated with mean IGF1 levels in the group as a whole (RZ0.42, PZ0.02).
Mean pooled free testosterone levels were higher in obese women and lower in women with AN than in normal-weight women (obese: 5.1G1.1 pg/ml, normal-weight: 1.5G0.3 pg/ml, AN: 0.8G0.4 pg/ml, P!0.0003). Mean pooled total testosterone levels were higher in the obese women than in the normalweight women or in the women with AN (obese: 26.3G5.4 ng/dl, normal-weight: 9.3G2.2 ng/dl, AN: 8.8G3.2 ng/dl, PZ0.0034; Table 1 ). Pooled E 2 levels were lower in the women with AN than in obese or normal-weight women (obese: 77G16 pg/ml, normalweight: 75G14 pg/ml, AN 23G4 pg/ml, PZ0.01). Mean pooled insulin levels were higher in the obese group of women than in normal-weight women or in women with AN (obese: 11.6G1.7 mIU/ml, normal-weight: 6.1G0.7 mIU/ml, AN: 5.3G0.8 mIU/ml, PZ0.001). There was no difference in mean pooled free fatty acid levels between the groups (obese: 0.43 G0.04 mEq/l, normal-weight: 0.41G0.03 mEq/l, AN: 0.46G0.05 mEq/l, PZ0.64). All the significant differences between groups delineated above remained significant after correcting for multiple comparisons. Mean pooled GH levels were inversely associated with mean pooled insulin levels (RZK0.56, PZ0.001), and there was a trend toward an inverse association with free testosterone levels (RZK0.34, PZ0.060). GH levels did not correlate significantly with E 2 , total testosterone, or free fatty acid levels.
Mean pooled IGF1 levels were positively associated with total testosterone (RZ0.35, PZ0.048) and free testosterone levels (RZ0.38, PZ0.032; Fig. 2) , and there was a trend toward an association with mean pooled E 2 levels (RZ0.33, PZ0.067). IGF1 levels did not correlate with insulin or free fatty acid levels. Dummy variables for AN and obesity were then entered into the models. For the relationship between IGF1 and total testosterone, both AN (PZ0.015) and obesity (PZ0.002) were significant predictors. For the association between IGF1 and free testosterone, obesity (PZ0.003), but not AN (PZ0.18), was the significant predictor in the model.
Stepwise regression models were constructed to investigate the determinants of the variability of pooled GH and IGF1 levels. In the group as a whole, trunk fat was a negative predictor and the strongest determinant of mean GH levels, accounting for 49% of the variability (R 2 Z0.49, P!0.0001), with an additional 7% of the variability attributable to E 2 (cumulative R 2 Z0.56,
PZ0.042).
There was a trend toward a negative effect of insulin (PZ0.084). When weight was entered into the model instead of trunk fat, weight was the strongest, and a negative predictor of GH (R 2 Z0.44, P!0.0001), with an additional 9% of the variability attributable to free testosterone (cumulative R 2 Z0.53, PZ0.031). In a stepwise regression model, free testosterone was a positive, and the only independent predictor of IGF1 levels, accounting for 14% of the variability (R 2 Z0.14, PZ0.032); this was unchanged when weight was entered into the model instead of trunk fat.
When the obese study subjects were excluded, i.e. stepwise regression models were constructed for the group of women with AN and normal-weight controls only, the model identified no significant determinants of GH levels. Free testosterone was a positive, and the only significant independent predictor of IGF1 levels, accounting for 36% of the variability (R 2 Z0.36, PZ0.003). There was a trend toward a positive effect of E 2 (PZ0.053).
Discussion
In this study, we investigated the determinants of IGF1 and GH levels throughout the weight spectrum, from obesity to AN. We measured potential determinants using overnight sampling for integrated measurements of these factors. We demonstrate that androgen levels are significant determinants of IGF1 levels throughout the weight spectrum, including at the low end of the weight range, in which relative hypoandrogenemia is present. We could not definitively establish that the relationships between IGF1 and androgens were comparable within the AN and obese groups; and further studies in a larger group of women would be necessary to investigate this comparison. Although the reduction in IGF1 levels may be adaptive in chronic starvation by reducing anabolism, it may also have In IGF1 (ng/ml) Figure 2 Pooled overnight IGF1 levels were associated with pooled free testosterone levels across the body composition spectrum (RZ0.38, PZ0.032) (log-transformed data shown).
deleterious effects, contributing to bone and muscle loss in women with AN. In addition, although the most significant determinant of GH levels in obese women was truncal adipose tissue mass, it was not a significant contributor to mean overnight GH levels in women with AN. These data support the hypothesis that GH secretion is differentially regulated at the low and high ends of the weight spectrum in women.
Testosterone is an important factor in the regulation of GH release, and has been shown in men to stimulate IGF1 levels independently of GH. Some, but not all, studies have demonstrated that testosterone independently stimulates or positively predicts IGF1 levels in men. Gibney et al. (17) administered GH with and without testosterone to men with hypopituitarism and demonstrated a greater increase in IGF1 levels in those men administered the combination than those administered GH alone, suggesting that testosterone augments the effects of GH on hepatic IGF1 production. In contrast, in a similar study, Fisker et al. (25) did not detect any change in total or free IGF1 levels when testosterone administration was added to GH replacement in hypopituitary men. Published data in women demonstrate that women with polycystic ovary syndrome have higher IGF1 levels than women of comparable weights but without hyperandrogemia (18) . Moreover, women receiving progestins with greater androgenecity (19) have higher IGF1 levels than those receiving progestins with less androgenecity. In addition, large crosssectional studies demonstrate an association between IGF1 levels and androgens in women (26) . In normalweight eumenorrheic young women, both GH secretion and serum IGF1 have been shown to increase in the periovulatory period in concert with increases in E 2 levels (27) . Although this may reflect a causative relationship between E 2 and IGF1, androgens increase at midcycle as well (23) , and it is not clear which gonadal steroids to attribute this relationship to. We have recently shown that free testosterone levels are an independent predictor of IGF1 levels in obese eumenorrheic women (4) . However, the current paper is the first to examine whether androgen levels are associated with IGF1 concentrations at the low end of the female weight spectrum. Because the relationship between IGF1 and most other known factors that affect the regulation of the hypothalamic-pituitary-IGF1 axis, including GH, BMI, and adiposity, are altered in a state of chronic starvation, it was not clear a priori whether the relationship observed in obese and normal-weight women of reproductive age would hold for women with AN, i.e. that low androgen levels are a factor contributing to low IGF1 levels in this population. Our data suggest that the relationship does hold. However, it should be noted that as causality cannot be established with a cross-sectional study, it is possible that IGF1 is stimulating androgen production or that a third factor, associated with both IGF1 and testosterone levels, is the cause of the association observed. Further studies are needed to clarify this point.
Nearly 50% of the variability of mean overnight GH levels was explained by truncal adipose tissue mass, as has been described previously by our group and others in obese women (3, 4) . Of note, this relationship was driven by the obese group of women, as the multivariate regression model did not identify truncal fat mass as a determinant of GH levels when obese women were excluded from the analysis. This is consistent with the hypothesis that GH secretion in states of undernutrition is driven by decreased circulating IGF1 through a feedback mechanism rather than body composition parameters or other circulating factors, e.g. free fatty acid or insulin levels. The lack of a statistically significant relationship in our study may also reflect the much smaller range in truncal adiposity among undernourished and normal-weight subjects when compared with obese women. However, it should be noted that our BMI range at the lower end was extremely low (13.2 kg/m 2 ). We therefore should have been able to detect such an association if it were present. As trunk and abdominal fat have been shown to be important determinants of GH secretion in nonobese study subjects (28, 29) , it is also possible that we were unable to detect an existing association between truncal fat and GH due to our sample size. It should also be noted that trunk fat, as determined by DXA, measures subcutaneous and visceral adipose tissue. In addition, when we entered weight into the multivariate models instead of truncal fat, we obtained similar results for weight as we had for truncal fat, suggesting that our study was not able to definitively identify the specific element of body composition responsible for the effects on GH secretion. Another important point is that GH was inversely associated with nocturnal insulin levels. Although it is certainly possible that insulin is merely a surrogate for obesity, it has also been shown in a mouse pituitary cell culture experiment (5) that insulin downregulates pituitary GH, GHRH receptor, and ghrelin receptor mRNA, suggesting a potential direct role of insulin in regulating GH.
Limitations of this study include its cross-sectional design and small size. In addition, we were able to sample peripheral blood only, and portal circulation of insulin and other hormones may differ from peripheral concentrations. Another limitation is that we pooled hourly serum samples for mean overnight GH levels. As the pulsatility of GH secretion in itself may be an important determinant of IGF1 (9, 30, 31), we might have been able to learn more about the regulation of the GH-IGF1 axis had we been able to characterize GH pulsatility over a 24-h period. Finally, although IGF1 is thought to be secreted into the circulation predominantly by hepatocytes, IGF1 derived from other sources, for example adipocytes, has not been ruled out as a possible source of circulating IGF1 in obese women and men.
In summary, we demonstrate that free testosterone is a significant determinant of IGF1 levels in women of reproductive age over a wide weight range. Further studies are warranted to determine whether the relationship between IGF1 and androgens is comparable within women with AN to that within women of normal weight and with obesity. It would also be important to determine whether androgen deficiency contributes to bone and skeletal muscle loss indirectly through its effect on IGF1 levels in states of chronic undernutrition.
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